Related Experiment Video
Updated: May 3, 2026
16:49
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
11.2K
The fragile relationship between hepatitis C virus and its human host
1University of California San Diego, La Jolla, CA, USA.
Topics in Antiviral Medicine
|February 18, 2014
Summary
Hepatitis C virus (HCV) responds better to direct-acting antivirals (DAA) than expected due to its acute phase vulnerability and DAA treatment disrupting viral-host equilibrium. This enhances immune responses against HCV.
Area of Science:
- Virology
- Immunology
- Hepatology
Background:
- Hepatitis C virus (HCV) suppression presents unexpected challenges compared to HIV, despite viral dynamics.
- Direct-acting antiviral (DAA) drugs have shown greater efficacy against HCV than initially predicted.
Purpose of the Study:
- To explore the mechanisms behind HCV's heightened responsiveness to potent antiviral therapy.
- To understand how DAA treatment impacts viral replication and host immune interactions in HCV infection.
Main Methods:
- Review of viral dynamics and replicative fidelity in HCV infection.
- Analysis of factors influencing HCV response to direct-acting antiviral (DAA) drugs.
- Examination of potential mechanisms of viral replication complex destabilization and immune evasion disruption.
Main Results:
- HCV's vulnerability during acute infection contributes to its responsiveness to DAAs.
- Increased DAA regimen potency accelerates viral decay kinetics.
- DAA treatment disrupts the established equilibrium between HCV and the host immune system.
Conclusions:
- Potent anti-HCV therapy may destabilize viral replication complexes, leading to infected cell cure.
- Rapid reduction of HCV by DAAs can undermine viral evasion of innate and adaptive immunity.
- These factors collectively enhance the antiviral efficacy of potent anti-HCV regimens.
Related Concept Videos
01:25Hepatitis
86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
01:28Viral Hepatitis I: Introduction
25
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
01:27Cytomegalovirus Disease
102
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
102
01:24Cirrhosis II: Pathophysiology
42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:23Cirrhosis I: Introduction
28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28